Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by Stifel Nicolaus in a research note issued to investors on Monday. They presently have a $60.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 39.96% from the company’s previous close.

Several other equities research analysts have also commented on the stock. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday. Deutsche Bank AG assumed coverage on shares of Esperion Therapeutics in a report on Friday. They issued a “buy” rating and a $48.00 price target for the company. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 9th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Esperion Therapeutics presently has a consensus rating of “Buy” and an average price target of $34.24.

Esperion Therapeutics (ESPR) traded down 3.32% during trading on Monday, reaching $42.87. The company’s stock had a trading volume of 503,549 shares. Esperion Therapeutics has a one year low of $9.40 and a one year high of $48.21. The firm’s market cap is $968.43 million. The company has a 50-day moving average of $34.90 and a 200 day moving average of $26.60.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same quarter last year, the company posted ($0.65) EPS. Analysts expect that Esperion Therapeutics will post ($6.78) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics, Inc. (ESPR) Rating Reiterated by Stifel Nicolaus” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/26/esperion-therapeutics-inc-espr-rating-reiterated-by-stifel-nicolaus.html.

Several hedge funds and other institutional investors have recently modified their holdings of ESPR. American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 921 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,282 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $158,000. Finally, C WorldWide Group Holding A S purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $162,000. 81.45% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.